항염증 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Anti-inflammatory Therapeutics Market size is expected to reach USD 191.46 Billion in 2034 from USD 116.65 Billion (2025) growing at a CAGR of 5.66% during 2026-2034.

The Global Anti-inflammatory Therapeutics Market is experiencing steady growth due to the increasing prevalence of inflammatory diseases such as arthritis, asthma, inflammatory bowel disease, and autoimmune disorders. Chronic inflammation has become a major health concern globally, leading to a rising demand for effective therapeutic solutions. Pharmaceutical companies are focusing on developing advanced anti-inflammatory drugs that help reduce symptoms and improve patient quality of life.

Several factors are contributing to the growth of this market, including advancements in drug discovery, increasing healthcare awareness, and growing investments in pharmaceutical research and development. Biologic therapies and targeted treatments are gaining popularity due to their ability to provide more precise treatment outcomes. Additionally, the aging global population and rising incidence of lifestyle-related diseases are further driving the demand for anti-inflammatory medications across healthcare systems.

In the coming years, the Global Anti-inflammatory Therapeutics Market is expected to benefit from continued innovation and expanding clinical research. Pharmaceutical companies are exploring new drug classes and combination therapies to enhance treatment effectiveness. The increasing adoption of personalized medicine and biologic therapies is also expected to open new avenues for market growth. With rising healthcare spending and ongoing medical advancements, the anti-inflammatory therapeutics market is poised for significant expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Anti-inflammatory Biologics
• NSAIDs
• Others

By Application

• Auto-Immune Diseases
• Respiratory Conditions
• Others

By Route of Administration

• Oral
• Injection
• Topical
• Inhalation

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• AbbVie Inc, Merck Co Inc, Johnson Johnson Services Inc, Pfizer Inc, Novartis AG, GlaxoSmithKline plc, Amgen Inc, F HoffmannLa Roche Ltd, AstraZeneca, Sanofi
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Anti-inflammatory Biologics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. NSAIDs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Auto-Immune Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Respiratory Conditions Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Injection Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Inhalation Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Drug Class
  • 8.2.2 By Application
  • 8.2.3 By Route Of Administration
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Drug Class
  • 8.3.2 By Application
  • 8.3.3 By Route Of Administration
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Drug Class
  • 8.4.2 By Application
  • 8.4.3 By Route Of Administration
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Drug Class
  • 8.5.2 By Application
  • 8.5.3 By Route Of Administration
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Drug Class
  • 8.6.2 By Application
  • 8.6.3 By Route Of Administration
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL ANTI-INFLAMMATORY THERAPEUTICS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 AbbVie Inc
  • 10.2.2 Merck & Co. Inc
  • 10.2.3 Johnson & Johnson Services Inc
  • 10.2.4 Pfizer Inc
  • 10.2.5 Novartis AG
  • 10.2.6 GlaxoSmithKline Plc
  • 10.2.7 Amgen Inc
  • 10.2.8 F. Hoffmann-La Roche Ltd
  • 10.2.9 AstraZeneca
  • 10.2.10 Sanofi